Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studies 
Patients and Methods
We conducted an integrated analysis of 12 phase II-III randomized, double-blind and/or open-label extension studies to evaluate short-term (12-26 weeks) efficacy and short-and longer-term (42-52 weeks) safety in men aged <75 years vs men aged ≥75 years. All men received oncedaily tadalafil 5 mg or placebo. The efficacy outcome was International Prostate Symptom Score (IPSS). Safety measurements included treatment-emergent adverse events (TEAEs), adverse events (AEs) leading to discontinuation, serious AEs (SAEs), and cardiovascular AEs. All analyses were intention-to-treat. Changes from baseline to efficacy endpoint and differences in changes between treatment groups were estimated as least-squares means using analysis of covariance models.
Results
Change in the mean IPSS was significantly different in men aged <75 years vs those aged ≥75 years across tadalafil and placebo groups (treatment-by-age interaction P = 0.034).
Tadalafil was not statistically significantly better than placebo in men aged ≥75 years, but effect size varied between studies. Maintenance of efficacy with tadalafil was observed across age groups. Short [1.8%] ). Long-term tadalafil safety data did not reveal clinically relevant differences between age groups. Limitations include exclusion of men with serious co-existing conditions and limited sample sizes of men aged ≥75 years.
Introduction
In aging men, LUTS associated with BPH (LUTS/BPH) are common [1] . Erectile dysfunction (ED) often coexists with LUTS/BPH and increases with LUTS severity [2] . Most men seeking treatment for either LUTS/BPH or ED have both conditions [3] .
A recent comprehensive literature search on the efficacy and safety of drugs commonly used to treat LUTS revealed a paucity of data in men aged ≥65 years for a-blockers, antimuscarinics, 5a-reductase inhibitors, phosphodiesterase type 5 (PDE5) inhibitors and b3-agonists. Data in men aged ≥75 years could not be identified for any of the drug classes [4] . Seven clinical studies [7, [13] [14] [15] [16] [17] [18] . Maintenance of efficacy from end of 12-week double-blind period to end of open-label extension period (42-to 52-week) included two LUTS/BPH clinical studies [17, 19] . Twelve-week safety of oncedaily tadalafil 5 mg vs placebo was based on 12 pooled studies, including the seven aforementioned LUTS/BPH studies [7, [13] [14] [15] [16] [17] [18] and five erectile dysfunction (ED) studies [20] [21] [22] [23] [24] . Long-term safety included two uncontrolled open-label LUTS/BPH extension studies [17, 19] and two uncontrolled openlabel ED extension studies [25] . Long-term Tadalafil, a long-lasting PDE5 inhibitor with an elimination half-life of 17.5 h, has been approved worldwide for ondemand or once-daily use in men with ED and for continuous use in men with signs or symptoms of BPH (LUTS/BPH) [5] [6] [7] [8] [9] . The efficacy and safety of tadalafil 5 mg, the licensed dose for LUTS/BPH, has been established in studies in predominantly middle-aged and older men [8] . Its effect in men aged ≥65 years has also been assessed [5, 10, 11] ; however, there is no information on tadalafil use in men aged ≥75 years, where comorbidity and concomitant medication are more common.
Because aging is often associated with altered pharmacokinetic/pharmacodynamic drug profiles secondary to changes in organ blood flow, metabolizing capacity and elimination patterns, reduced physiological reserve of organ function and drug-drug interactions, there may be an increased prevalence of adverse events (AEs) or a unique AE profile [12] . The aim of the present analysis was to assess the efficacy and safety of once-daily tadalafil (5 mg) in men aged ≥75 years with LUTS/BPH (some of whom had ED) and safety in men aged ≥75 years with ED based on data from phase II/III studies worldwide.
Patients and Methods

Study Design
Data were pooled from multicentre, randomized, doubleblind, placebo-controlled clinical studies and/or open-label extension studies to evaluate the short-term efficacy and maintenance of effect for LUTS/BPH and short-and longterm safety (LUTS/BPH and/or ED) of once-daily tadalafil 5 mg in men aged ≥75 years ( Fig. 1) [7, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . Data from men aged <75 years were used as a comparator. Studies of tadalafil for ED were included in the safety analysis to increase the sample size. Only placebo-controlled, suitably powered studies from the sponsor (Eli Lilly and Company, Indianapolis, IN, USA) were included to secure a more homogeneous population for this pooled analysis.
No ethical committee approval was required for this integrated analysis. Each underlying study was performed in accordance with all applicable laws and regulations. Institutional review boards for each site approved each study and all men provided written informed consent before initiating any trial.
Study Population
The inclusion and exclusion criteria, which varied slightly across LUTS/BPH studies, have been previously described [7, [13] [14] [15] [16] [17] [18] [19] . Briefly, LUTS/BPH study eligibility included men aged ≥45 years with LUTS/BPH for >6 months, moderateto-severe symptoms based on an IPSS ≥13, and a maximum urinary flow rate ≥4 and ≤15 mL/s before the placebo leadin period. In one study, men also had to have ED and be sexually active with a female partner [15] . In Asian studies, a prostate volume ≥20 mL according to ultrasonography was required, but prostate size was not assessed in the nonAsian studies. For all studies, men were excluded if their PSA level was >10 ng/mL (in men with a PSA of 4-10 ng/ mL, negative prostate biopsies for malignancy within 12 months were required), post-void residual urine volume was ≥300 mL at screening visit, or finasteride or dutasteride was taken within 3-12 months [13] . Finasteride, dutasteride or a-adrenergic receptors antagonists were not allowed after enrolment. Men with unstable cardiovascular disease: myocardial infarction within last 90 days; unstable angina or angina occurring during sexual intercourse; New York Heart Association Class ≥2-3 heart failure in previous 6 months; *Men may be counted in more than one category. Primary exclusionary medical conditions included clinically significant renal (creatinine clearance <30 mL/min) or severe hepatic insufficiency, cardiovascular conditions such as clinically significant angina, recent myocardial infarction or poorly controlled blood pressure, and a recent history of stroke or spinal cord injury. † Includes terms related to pulmonary hypertension, cardiac valve disease, cardiac murmur, septal defects and pacemaker-related procedures. ‡ Includes terms related to peripheral aneurysms or dissections; peripheral atherosclerosis; and other miscellaneous vascular disorders.
§ Per LUTS/BPH study exclusion criteria, current systemic treatment with a potent cytochrome P450 3A4 (CYP3A4) inhibitor was prohibited. Data presented here do not include potent CYP3A4i use.
¶ For the LUTS/BPH studies, men were not allowed to continue on a-blockers. Accordingly, these drugs were discontinued on enrolment, followed by a washout period, before initiating study treatment.
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© 2016 The Authors BJU International © 2016 BJU International uncontrolled arrhythmias, hypotension (<90/50 mmHg), or uncontrolled hypertension (e.g. systolic blood pressure >160-170 mmHg or diastolic blood pressure >100 mmHg); stroke within previous 6 months; and current treatment with nitrates were excluded. All of these exclusions contribute to the current label of conditions where tadalafil is not recommended [8] .
Efficacy and Safety Outcome Measures
Short-(12-26 weeks) and longer-term efficacy (42-52 weeks) of tadalafil for LUTS/BPH, stratified by age (≥75 years vs <75 years), was based on the following outcome measures: total IPSS; IPSS storage and voiding subscores; and IPSS-quality of life (QoL).
Short-and long-term safety outcome measures included: treatment-emergent AEs (TEAEs); AEs that led to discontinuation; serious AEs (SAEs); vital signs analyses; and orthostatic blood pressure assessment.
Statistical Analysis
Analyses were performed on an intention-to-treat basis for all randomized men who started double-blind study medication. Demographic and baseline clinical characteristics of the men, comorbidities, concurrent medications and safety data were summarized by treatment group and within each age group (≥75 years vs <75 years) using descriptive statistics.
Short-term efficacy analyses assessed changes from baseline (defined as randomization visit [end of placebo lead-in period or start of double-blind treatment period]) to endpoint (defined as data collected at week 12 of doubleblind period, or last non-missing, post-baseline data). Changes from baseline to endpoint and differences in these changes between placebo and tadalafil 5 mg treatment groups were estimated as least-squares means using analysis of covariance models. The model included terms for protocol, centred-baseline value, treatment group, geographic region, age category, treatment-by-age category interaction, centred-baseline-by-treatment interaction, and treatment-bygeographic region interaction. Between-group comparisons (tadalafil vs placebo) within each age category were performed at the two-sided 0.05 significance level. Interaction tests for differences in symptoms for men aged ≥75 years treated with tadalafil or placebo vs men aged <75 years treated with tadalafil or placebo were performed at a two-sided 0.10 significance level.
Results
Twelve studies including 3 309 men formed the sample for this pooled analysis. Baseline demographics and characteristics for all randomized men (3 012 men [91%] (Table 1) ; however, men aged ≥75 years had more comorbidities and received more concomitant medications (Table 2) .
Efficacy with Regard to LUTS/BPH
Efficacy at Weeks 12-26
Based on the integrated analyses from seven 12-week studies, the changes in mean IPSS, IPSS storage subscore, IPSS voiding subscore and IPSS-QoL index were statistically significantly different in men aged ≥75 years vs men aged <75 years across tadalafil and placebo treatment groups (treatment-by-age interaction term P = 0.034, P = 0.045, P = 0.068 and P = 0.018). The magnitude of improvement in LUTS/BPH, as assessed by placebo-adjusted mean total IPSS, IPSS storage subscore, IPSS voiding subscore and IPSS-QoL index differences after treatment with tadalafil were statistically significantly smaller in men aged ≥75 years vs men aged <75 years (Table 3) ; however, in some individual 12-week studies, tadalafil-treated men aged ≥75 years had a similar improvement in total IPSS compared with tadalafiltreated men aged <75 years (Table 4) .
Maintenance of Efficacy
Regardless of assigned treatment group in the double-blind phase, mean change in total IPSS score for 99 men aged ≥75 years vs 711 men aged <75 years was small from the end of the 12-week double-blind period to the end of the open-label extension period for men on tadalafil (0.1 vs À1.2, respectively), suggesting maintenance of efficacy in both age groups. Figure 2 shows the mean change in total IPSS over time during the open-label extension phase for the subset of men aged ≥75 years who received tadalafil in the double-blind phase. 
Safety
Safety at Weeks 0-12
A higher proportion of men aged ≥75 years (tadalafil 33.8%, placebo 26.6%) experienced TEAEs than men aged <75 years (tadalafil 30.3%, placebo 23.3%; Table 5 ). For men aged ≥75 years, diarrhoea (4.5% vs 2.8%) and dizziness (3.2% vs 0.7%) rates were numerically slightly higher, but not statistically different between tadalafil vs placebo groups.
Among men aged ≥75 years, one (0.7%) in the placebo group and five (3.2%) in the tadalafil group reported dizziness as a TEAE. All events were mild in severity, none led to early study discontinuation or were associated with clinical sequelae, and all but one event resolved during treatment with tadalafil. One tadalafil-treated man had treatmentemergent orthostasis (10 mmHg reduction in diastolic blood pressure upon standing, temporally unrelated to the reporting of dizziness), and another experienced dizziness during orthostatic vital sign assessment, although no criteria for orthostatic hypotension were met. All five tadalafil-treated men had multiple concurrent illnesses.
At least one cardiovascular TEAE in tadalafil-treated men was reported for four men (2.6%) aged ≥75 years and 30 men (1.8%) aged <75 years. The corresponding rates in placebo recipients were five (3.5%) and 19 (1.4%), respectively. Five cardiovascular events were reported in four tadalafil-treated men aged ≥75 years, including one acute myocardial infarction (SAE and premature discontinuation), angina pectoris, coronary artery disease (SAE), peripheral oedema, and abnormal myocardial perfusion scan. Only the acute myocardial infarction was considered by the investigator to be possibly related to treatment with tadalafil.
The percentage of men discontinuing the study drug because of an AE was similar for the ≥75-year (6/297, 2.0%) and the <75-year age groups (72/3 012, 2.4%; The four SAEs in tadalafil-treated men aged ≥75 years included: myocardial infarction 2.5 months postrandomization, coronary artery disease 8 weeks postrandomization, renal cancer 6 months post-randomization, and femur fracture secondary to accident 26 days postrandomization.
Small mean decreases in diastolic and systolic blood pressure were observed for tadalafil-treated men in both age groups. None of the changes were significantly different from placebo. There was no evidence for a statistically significant treatmentby-age interaction for change in blood pressure (P value for interaction 0.486 and 0.633 for diastolic and systolic blood pressure, respectively). No treatment group difference was found in the percentage of men with clinically significant low systolic (<90 mmHg) or diastolic (<60 mmHg) blood pressure in either age group, and no statistical evidence for an age-by-treatment interaction was found. Based on available data from two LUTS/BPH studies (n = 369 tadalafil, n = 364 placebo) [14, 15] , the percentages of men meeting at least one criterion for treatment-emergent orthostatic hypotension were similar in the two age groups, regardless of treatment (Fig. 3) . The frequency of TEAEs was generally higher in the openlabel studies and in both age groups compared with the double-blind studies. The overall frequency of TEAEs was similar in both age groups of men who received tadalafil for at least 6 months: 63 (49.6%) men aged ≥75 years reported at least one TEAE vs 611 (52.4%) men aged <75 years (Table 6 ). Types of TEAE in both age groups were generally similar. The most common TEAEs (≥3%) in men aged ≥75 years were insomnia, diarrhoea, nasopharyngitis and osteoarthritis.
A higher percentage of discontinuations because of AEs was reported for men aged ≥75 years (12 [9.4%]) vs men aged <75 years (70 [6.0%]) after long-term exposure to tadalafil (Table 6 ). Individual events in men aged ≥75 years considered unrelated to tadalafil or study procedures contributed to the higher percentage of discontinuations (e.g. lung neoplasm, pancreatic carcinoma and prostatitis).
A higher percentage of SAEs was reported for men aged ≥75 years (12 [9.4%]) vs men aged <75 years (53 [4.5%]) after long-term exposure to tadalafil (Table 6 ). For the ≥75-year age group, 15 SAEs were reported, including osteoarthritis (n = 2) and one each of atrial fibrillation, back pain, benign lung neoplasm, congestive heart failure, acute cholecystitis, colonic polyps, fibula fracture, hip arthroplasty, cholestatic jaundice, myocardial infarction, pancreatic carcinoma, renal cancer and urinary retention.
Discussion
In the present integrated analysis the improvements in LUTS/ BPH were statistically significantly different in men aged ≥75 years vs men aged ≤75 years across tadalafil and placebo treatment groups. Tadalafil was well tolerated regardless of age in men with LUTS/BPH and/or ED. Most TEAEs were reported at similar rates in the two age groups. Discontinuation did not seem to increase with age and there were only few SAEs in men aged ≥75 years, which were all unrelated to tadalafil therapy. No new cardiovascular safety concerns were identified in tadalafil-treated men aged ≥75 years.
Based on analyses of total IPSS, IPSS storage and IPSS voiding subscores and IPSS-QoL index from baseline to end of 12-week treatment, efficacy in men aged ≥75 years was statistically significantly lower than that observed in men aged <75 years; however, there was considerable variability across Table 5 Short-term integrated safety in 3 309 men from 12 placebo-controlled studies enrolling men with LUTS associated with BPH and/or erectile dysfunction (aged ≥75 years vs <75 years) by decreasing frequency in men aged ≥75 years for tadalafil.
Study drug
Age group <75 years ≥75 years Tadalafil Table 4 ), suggesting that some men aged ≥75 years may still experience a clinically significant improvement with tadalafil. Additionally, the overall sample size was small and may not reflect the total experience of older men. Yet, most tadalafil studies in men with LUTS/BPH had adequately powered sample size per treatment arm (>150 patients) [7, [13] [14] [15] [16] . The small sample size of men aged ≥75 years also precluded any meaningful uni-and multivariate analyses. Given tadalafil's mechanism of action, the loss of smooth and striated muscle tissue in aging superimposed upon smooth muscle loss from cardiovascular disease, together with generally less CNS descending urinary inhibition and increased incidence of cerebrovascular disorders (Table 2) , may explain the observed reduced effect in older men. Higher use of concurrent medication and greater prevalence of comorbidity in these men may also be a contributing factor in the observed reduced efficacy, similar to that previously reported [26] .
Changes in IPSS in men aged >65 years treated with oncedaily tadalafil 5 mg for 12 weeks were recently assessed in a predominantly white study population [5] and in a predominantly Japanese study population [11] . While all age cohorts experienced an improvement with tadalafil, the predominantly Japanese men aged >65 years reported statistically significantly lower improvement. Regardless, in a similar fashion to younger men, men aged >65 years receiving tadalafil for up to 52 weeks during open-label extension studies maintained their reduction in symptoms long-term (per total IPSS) [17, 19] .
The short-and long-term safety profiles of tadalafil in men aged ≥75 years with LUTS/BPH (many of whom also have ED) and men aged ≥75 years with ED (many of whom also have LUTS/BPH) were generally similar to men aged <75 years with these conditions, despite a higher use of concomitant medications. Possible exceptions included numerically higher rates of diarrhoea and dizziness rates in men aged ≥75 years. The small numerically higher incidence of diarrhoea observed in tadalafil-treated men aged ≥75 years (4.5%) vs men aged <75 years (1.0%) is a recognized AE in older men treated with tadalafil asrequired (p.r.n.) for ED (data on file, Eli Lilly and Company). Dizziness was also more commonly reported by tadalafil-treated men aged ≥75 years (3.2%) vs men aged <75 years (0.7%). Reported dizziness did not correspond to hypotensive events. Nonetheless, the mild systemic vasodilatory properties of tadalafil may result in unwanted decreases in blood pressure and dizziness, especially in men with left ventricular outflow obstruction or in men using nitrates or non-selective a 1 -adrenoceptor antagonists and should not be used together [8] . Overall tolerability, as assessed by discontinuations because of AEs, was similar in both age groups.
Other pooled analyses in men of all ages [5, 26] , together with two reports comparing men aged >65 vs <65 years [5] or aged ≥65 vs ≤65 years [11] corroborate these safety findings.
Data from an integrated analysis of~1 500 US and European men with LUTS/BPH treated with once-daily tadalafil 5 mg did not identify any statistically significant difference in TEAEs between men with or without cardiovascular disease when stratified by age (≥65 years vs <65 years) [5] ; however, most cardiovascular events occurred in men with reported pre-existing cardiovascular risk factors. Likewise, in 12 500 men with ED, of whom 5 939 tadalafil-treated men (48%) had diabetes mellitus, hyperlipidaemia, hypertension and/or coronary artery disease, tadalafil (2-50 mg as needed, three times/week, or once/day dosing) was not associated with an increased risk of serious cardiovascular AEs [27] . In an observational cohort study of 6 229 tadalafil-treated men (median age 61 years), cardiovascular events included chest pain in 20, angina in 18, myocardial infarction in 15 (including six fatal) and ischaemic heart disease (IHD) in 11 men (including five fatal events) [28] . Myocardial infarction rates were not higher after treatment with tadalafil 5 mg, and The treatment of older men with LUTS/BPH may be particularly challenging because of the presence of clinically significant comorbidity and related polypharmacy; selected treatments should, if possible, have proven efficacy and safety in older populations. Until recently, data that specifically addressed the needs of older patients were lacking, requiring treating physicians to extrapolate findings from studies in a largely middle-aged, healthier population. Avoidance of drugdrug interactions is important, as is limiting the burden of adding more medications than absolutely necessary. Tadalafil has advantages for the treatment of men with LUTS/BPH and ED in offering a single medication for treatment of closely allied conditions. Likewise, tadalafil could potentially address storage symptoms without the adverse tolerability profile or potential for impaired cognition associated with antimuscarinic agents [29] or the problem of ejaculatory dysfunction associated with a-blockers [30] ; however, the present pooled analyses suggest little overall benefit in LUTS/BPH, albeit with considerable variability. By comparison, antimuscarinic agents are also known to be less efficacious in the elderly [31] .
The findings of the present integrated analysis have several limitations. Because of the controlled settings of clinical studies, certain serious co-existing conditions were excluded (e.g. unstable cardiovascular disease, uncontrolled diabetes mellitus, clinically significant hepatobiliary or renal disease), thus the analysed patient population does not necessarily represent everyone with LUTS/BPH and/or ED. Such patients, however, should not use PDE5 inhibitors [8] . In addition, these results were derived from a post hoc analysis with a relatively small number of men aged ≥75 years, which limits the ability to generalize the results to patients in clinical practice. Furthermore, plausible interference of agerelated confounding factors on the efficacy cannot be excluded in the absence of uni-/multivariate analyses. A prospective suitably powered study in men aged ≥75 years would provide more conclusive results. Preparatory quantitative and qualitative work to establish what constitutes a clinically meaningful improvement in men aged ≥75 years compared with younger men would also be informative.
In conclusion, the change in LUTS/BPH (total IPSS, storage IPSS, voiding IPSS and IPSS-QoL) was statistically significantly different in men aged ≥75 years vs men aged <75 years across tadalafil and placebo treatment groups. Once-daily tadalafil 5 mg was statistically significantly less efficacious in the treatment of LUTS/BPH in men aged ≥75 years than in younger men (<75 years), albeit with considerable variability between studies. Aside from events commonly associated with tadalafil treatment, the types of TEAE reported in men aged ≥75 years were generally not unexpected in a population with multiple comorbidities and concomitant medications. No new safety signals for cardiovascular disease were observed in men aged ≥75 years after treatment with tadalafil. While clinicians may continue to prescribe tadalafil in men aged ≥75 years, efficacy and safety in this population should be closely monitored.
